Amylyx Pharmaceuticals, Inc. Capital Expenditures
Amylyx Pharmaceuticals, Inc. (AMLX) reported Capital Expenditures of $30.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-08-06
- Amylyx Pharmaceuticals, Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-12-31 was $86.00K, a 330.00% increase year-over-year.
- Amylyx Pharmaceuticals, Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-09-30 was $24.00K.
- Amylyx Pharmaceuticals, Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-06-30 was $17.00K, a 80.90% decline year-over-year.
- Amylyx Pharmaceuticals, Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-03-31 was $11.00K, a 83.58% decline year-over-year.
- Amylyx Pharmaceuticals, Inc. payments to acquire property, plant, and equipment for fiscal 2025 was $138.00K, a 12.10% decline from fiscal 2024.
- Amylyx Pharmaceuticals, Inc. payments to acquire property, plant, and equipment for fiscal 2024 was $157.00K, a 87.35% decline from fiscal 2023.
- Amylyx Pharmaceuticals, Inc. payments to acquire property, plant, and equipment for fiscal 2023 was $1.24M, a 50.87% decline from fiscal 2022.
- Amylyx Pharmaceuticals, Inc. payments to acquire property, plant, and equipment for fiscal 2022 was $2.53M, a 615.58% increase from fiscal 2021.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2026-06-30 | $30.00K 10-Q · filed 2026-08-06 | |||
| 2025-12-31 | $86.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $110.00K derived: sum of 2 quarters · filed 2026-03-03 | $127.00K derived: sum of 3 quarters · filed 2026-08-06 | $138.00K 10-K · filed 2026-03-03 |
| 2025-09-30 | $24.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $41.00K derived: sum of 2 quarters · filed 2026-08-06 | $52.00K 10-Q · filed 2025-11-06 | $72.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $17.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $28.00K 10-Q · filed 2026-08-06 | $48.00K derived: sum of 3 quarters · filed 2026-08-06 | $29.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $11.00K 10-Q · filed 2026-05-07 | $31.00K derived: sum of 2 quarters · filed 2026-05-07 | $12.00K derived: sum of 3 quarters · filed 2026-05-07 | $101.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $20.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $1.00K derived: sum of 2 quarters · filed 2026-03-03 | $90.00K derived: sum of 3 quarters · filed 2026-03-03 | $157.00K 10-K · filed 2026-03-03 |
| 2024-09-30 | -$19.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $70.00K derived: sum of 2 quarters · filed 2025-11-06 | $137.00K 10-Q · filed 2025-11-06 | $493.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $89.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $156.00K 10-Q · filed 2025-08-07 | $512.00K derived: sum of 3 quarters · filed 2025-08-07 | $869.00K derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $67.00K 10-Q · filed 2025-05-08 | $423.00K derived: sum of 2 quarters · filed 2025-05-08 | $780.00K derived: sum of 3 quarters · filed 2025-05-08 | $1.06M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $356.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | $713.00K derived: sum of 2 quarters · filed 2025-03-04 | $991.00K derived: sum of 3 quarters · filed 2025-03-04 | $1.24M 10-K · filed 2025-03-04 |
| 2023-09-30 | $357.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $635.00K derived: sum of 2 quarters · filed 2024-11-07 | $885.00K 10-Q · filed 2024-11-07 | $1.50M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $278.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $528.00K 10-Q · filed 2024-08-08 | $1.15M derived: sum of 3 quarters · filed 2024-08-08 | $1.61M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $250.00K 10-Q · filed 2024-05-09 | $870.00K derived: sum of 2 quarters · filed 2024-05-09 | $1.33M derived: sum of 3 quarters · filed 2024-05-09 | $2.43M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $620.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $1.08M derived: sum of 2 quarters · filed 2024-02-22 | $2.18M derived: sum of 3 quarters · filed 2024-02-22 | $2.53M 10-K · filed 2024-02-22 |
| 2022-09-30 | $459.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $1.56M derived: sum of 2 quarters · filed 2023-11-09 | $1.91M 10-Q · filed 2023-11-09 | $2.09M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $1.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $1.45M 10-Q · filed 2023-08-10 | $1.63M derived: sum of 3 quarters · filed 2024-02-22 | $1.79M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $342.00K 10-Q · filed 2023-05-11 | $528.00K derived: sum of 2 quarters · filed 2024-02-22 | $681.00K derived: sum of 3 quarters · filed 2024-02-22 | $681.00K derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $186.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $339.00K derived: sum of 2 quarters · filed 2024-02-22 | $339.00K derived: sum of 3 quarters · filed 2024-02-22 | $353.00K 10-K · filed 2024-02-22 |
| 2021-09-30 | $153.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $153.00K derived: sum of 2 quarters · filed 2022-11-10 | $167.00K 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $14.00K 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | $14.00K 10-Q · filed 2022-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |